Insights

Seth Wander, MD, PhD, Massachusetts General Hospital

Videos

Novel Endocrine Agents for Patients With HR-Positive Breast Cancer

05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...

At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic v breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Denise Yardley, MD, Sarah Cannon Research Institute

Videos

Is Age 50 Relevant for Decisions in Early HR-Positive Breast Cancer?

05/08/2024

Featuring Denise Yardley, MD

At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center

Videos

Sequential Antibody Drug Conjugates for Patients With Metastatic Breast Cancer

05/08/2024

Featuring Neil Iyengar, MD

At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.

At Great Debates and Updates in...

05/08/2024

Oncology

Conference Coverage

Use of Liquid Biopsies to Reduce Time to Treatment for Patients With Lung Cancer

05/07/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.

At the Great Debates and Updates...

05/07/2024

Oncology

Conference Coverage

Discussing the Need of Adjuvant Treatment After Neoadjuvant in Early Stage Lung Cancer

05/06/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.

At the Great Debates and Updates...

05/06/2024

Oncology

Noa Biran, MD, John Theurer Cancer Center

Q&As

Step-Up Dosing for Multiple Myeloma Treatment in the Outpatient Setting

05/06/2024

Featuring Noa Biran, MD

Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.

Noa Biran, MD, explains the...

05/06/2024

Oncology

Noa Biran, MD, Hackensack Meridian Health

Conference Coverage

Evaluating Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma

05/06/2024

Featuring Noa Biran, MD

Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.

Noa Biran, MD, evaluates a...

05/06/2024

Oncology

Conference Coverage

Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment

05/06/2024

Featuring Sam Yamshon, MD

Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.

Sam Yamshon, MD, discusses the...

05/06/2024

Oncology

Jennifer Amengual, MD, Columbia University

Conference Coverage

Novel Therapeutic Targets for Elderly Patients With Diffuse Large B-Cell Lymphoma

05/06/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.

At the Lymphoma, Leukemia &...

05/06/2024

Oncology

Balazs Halmos, MD, Montefiore Einstein Comprehensive Cancer Center

Conference Coverage

Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer

05/03/2024

Featuring Balazs Halmos, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.

At the Great Debates and Updates...

05/03/2024

Oncology

Recent News

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma

04/23/2024

Stephanie Holland

Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...

Results from the phase 2 NRG...

04/23/2024

Oncology

News

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology